Treatment and Prevention of Opioid Use Disorder: Challenges and Opportunities

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Treatment for opioid use disorder in the United States evolved in response to changing federal policy and advances in science. Inpatient care began in 1935 with the US Public Health Service Hospitals in Lexington, Kentucky, and Fort Worth, Texas. Outpatient clinics emerged in the 1960s to provide aftercare. Research advances led to opioid agonist and opioid antagonist therapies. When patients complete opioid withdrawal, return to use is often rapid and frequently deadly. US and international authorities recommend opioid agonist therapy (i.e., methadone or buprenorphine). Opioid antagonist therapy (i.e., extended-release naltrexone) may also inhibit return to use. Prevention efforts emphasize public and prescriber education, use of prescription drug monitoring programs, and safe medication disposal options. Overdose education and naloxone distribution promote access to rescue medication and reduce opioid overdose fatalities. Opioid use disorder prevention and treatment must embrace evidence-based care and integrate with physical and mental health care.

Original languageEnglish (US)
Pages (from-to)525-541
Number of pages17
JournalAnnual Review of Public Health
Volume39
DOIs
StatePublished - Apr 1 2018

Fingerprint

Opioid Analgesics
Narcotic Antagonists
Therapeutics
Education
Buprenorphine
Aftercare
Naltrexone
United States Public Health Service
Prescription Drugs
Drug Monitoring
Methadone
Naloxone
Ambulatory Care Facilities
Inpatients
Mental Health
Delivery of Health Care
Research

Keywords

  • opioid agonist therapy
  • opioid antagonist therapy
  • opioid overdose prevention
  • opioid use disorder
  • treatment for opioid use disorder

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Treatment and Prevention of Opioid Use Disorder : Challenges and Opportunities. / McCarty, Dennis; Priest, Kelsey C.; Korthuis, Philip (Todd).

In: Annual Review of Public Health, Vol. 39, 01.04.2018, p. 525-541.

Research output: Contribution to journalReview article

@article{86f2f80308ec4fb5b1b78a520681e617,
title = "Treatment and Prevention of Opioid Use Disorder: Challenges and Opportunities",
abstract = "Treatment for opioid use disorder in the United States evolved in response to changing federal policy and advances in science. Inpatient care began in 1935 with the US Public Health Service Hospitals in Lexington, Kentucky, and Fort Worth, Texas. Outpatient clinics emerged in the 1960s to provide aftercare. Research advances led to opioid agonist and opioid antagonist therapies. When patients complete opioid withdrawal, return to use is often rapid and frequently deadly. US and international authorities recommend opioid agonist therapy (i.e., methadone or buprenorphine). Opioid antagonist therapy (i.e., extended-release naltrexone) may also inhibit return to use. Prevention efforts emphasize public and prescriber education, use of prescription drug monitoring programs, and safe medication disposal options. Overdose education and naloxone distribution promote access to rescue medication and reduce opioid overdose fatalities. Opioid use disorder prevention and treatment must embrace evidence-based care and integrate with physical and mental health care.",
keywords = "opioid agonist therapy, opioid antagonist therapy, opioid overdose prevention, opioid use disorder, treatment for opioid use disorder",
author = "Dennis McCarty and Priest, {Kelsey C.} and Korthuis, {Philip (Todd)}",
year = "2018",
month = "4",
day = "1",
doi = "10.1146/annurev-publhealth-040617-013526",
language = "English (US)",
volume = "39",
pages = "525--541",
journal = "Annual Review of Public Health",
issn = "0164-7525",
publisher = "Annual Reviews Inc.",

}

TY - JOUR

T1 - Treatment and Prevention of Opioid Use Disorder

T2 - Challenges and Opportunities

AU - McCarty, Dennis

AU - Priest, Kelsey C.

AU - Korthuis, Philip (Todd)

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Treatment for opioid use disorder in the United States evolved in response to changing federal policy and advances in science. Inpatient care began in 1935 with the US Public Health Service Hospitals in Lexington, Kentucky, and Fort Worth, Texas. Outpatient clinics emerged in the 1960s to provide aftercare. Research advances led to opioid agonist and opioid antagonist therapies. When patients complete opioid withdrawal, return to use is often rapid and frequently deadly. US and international authorities recommend opioid agonist therapy (i.e., methadone or buprenorphine). Opioid antagonist therapy (i.e., extended-release naltrexone) may also inhibit return to use. Prevention efforts emphasize public and prescriber education, use of prescription drug monitoring programs, and safe medication disposal options. Overdose education and naloxone distribution promote access to rescue medication and reduce opioid overdose fatalities. Opioid use disorder prevention and treatment must embrace evidence-based care and integrate with physical and mental health care.

AB - Treatment for opioid use disorder in the United States evolved in response to changing federal policy and advances in science. Inpatient care began in 1935 with the US Public Health Service Hospitals in Lexington, Kentucky, and Fort Worth, Texas. Outpatient clinics emerged in the 1960s to provide aftercare. Research advances led to opioid agonist and opioid antagonist therapies. When patients complete opioid withdrawal, return to use is often rapid and frequently deadly. US and international authorities recommend opioid agonist therapy (i.e., methadone or buprenorphine). Opioid antagonist therapy (i.e., extended-release naltrexone) may also inhibit return to use. Prevention efforts emphasize public and prescriber education, use of prescription drug monitoring programs, and safe medication disposal options. Overdose education and naloxone distribution promote access to rescue medication and reduce opioid overdose fatalities. Opioid use disorder prevention and treatment must embrace evidence-based care and integrate with physical and mental health care.

KW - opioid agonist therapy

KW - opioid antagonist therapy

KW - opioid overdose prevention

KW - opioid use disorder

KW - treatment for opioid use disorder

UR - http://www.scopus.com/inward/record.url?scp=85044855760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044855760&partnerID=8YFLogxK

U2 - 10.1146/annurev-publhealth-040617-013526

DO - 10.1146/annurev-publhealth-040617-013526

M3 - Review article

C2 - 29272165

AN - SCOPUS:85044855760

VL - 39

SP - 525

EP - 541

JO - Annual Review of Public Health

JF - Annual Review of Public Health

SN - 0164-7525

ER -